G1 Therapeutics
700 Park Offices Drive
Suite 200
Research Triangle Park
North Carolina
27709
United States
Website: http://www.g1therapeutics.com/
228 articles about G1 Therapeutics
-
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer
12/19/2018
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with topotecan as a treatment for 2nd-/3rd-line small cell lung cancer (2/3L SCLC).
-
G1 Therapeutics Presents Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin for Treatment of First-Line Small Cell Lung Cancer
10/21/2018
New data analyses highlight myelopreservation and immune system benefits of trilaciclib in combination with chemotherapy
-
A mid-stage program aimed at treating myelosuppression in lung cancer patients undergoing chemotherapy is yielding positive results.
-
G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018
2/14/2018
The company will host a webcast and conference call at 4:30 p.m. EST to discuss the financial results and provide an update on its corporate activities and product pipeline.
-
GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cancer
1/3/2018
Financial terms were not disclosed.
-
G1 Therapeutics Added to Nasdaq Biotechnology Index
12/18/2017
G1 Therapeutics today announced that it has been selected for addition to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 18, 2017.
-
G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/7/2017
The inducement grant to Mr. Phillips consisted of an option to purchase up to 150,000 shares of common stock.
-
G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
11/28/2017
Phase 1b/2 study evaluating AstraZeneca’s Tagrisso® and G1T38 in EGFR mutation-positive non-small cell lung cancer is expected to initiate in the first quarter of 2018.
-
G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
11/8/2017
Operating expenses were $15.9 million for the third quarter of 2017, compared to $6.6 million for the third quarter of 2016.
-
G1 Therapeutics Makes Key Executive Appointments
11/8/2017
The company appointed Barclay (Buck) Phillips as CFO and Sr. VP, Corporate Development, and Chandra Lovejoy as VP, Global Regulatory Affairs.
-
G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response
11/6/2017
Intermittent dosing of G1’s CDK4/6 inhibitor trilaciclib enhances anti-tumor efficacy of checkpoint inhibitors in preclinical models.
-
G1 Therapeutics Added To Russell 2000, 3000® And Microcap Indexes
9/18/2017
-
G1 Therapeutics Reports Second Quarter 2017 Financial Results And Recent Operational Highlights
8/9/2017
-
G1 Therapeutics Makes Key Appointments To Management Team
8/3/2017
-
G1 Therapeutics To Ring Nasdaq Stock Market Closing Bell On Wednesday, August 2, 2017
7/27/2017
-
G1 Therapeutics Appoints Sir Andrew Witty To Board Of Directors
7/13/2017
-
G1 Therapeutics Announces Closing Of Initial Public Offering
5/23/2017
-
Cancer Biotech G1 Therapeutics Grabs $105 Million in IPO
5/17/2017
-
G1 Therapeutics Announces Launch Of Initial Public Offering
5/8/2017
-
Cancer Biotech G1 Therapeutics Files for $115 Million IPO
4/19/2017